Search results
<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PVQMF29>m_auth=>m_preview=>m_cookies_win=x" height="0" width="0" style="display:none;visibility ...
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.
Join Sandoz, a global leader in generic and biosimilar medicines, and shape the future of healthcare with a diverse and dynamic team.
Oct 4, 2023 · Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off. Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange.
Oct 4, 2023 · Sandoz planned spin-off updates at Novartis Q2 2023 Financial Results. The Novartis Board of Directors has unanimously endorsed the proposed separation of Sandoz to create an independent company by way of a 100% spin-off.
At Sandoz, we are committed to making access happen for patients around the world. Our purpose and ambition is to shape the future of medicine by providing high-quality generic and biosimilar medicines at affordable prices. Find out more about our vision, values, and strategy on our website.
Discover who we are at Sandoz, a global leader in generic and biosimilar medicines, and how we strive to improve and extend people's lives.
Learn more about Sandoz US, a leader in generic and biosimilar medicines, who we are, what we do, and how we make access happen for patients.
Mar 21, 2023 · Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®*. With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation.
Stay updated with the latest news and developments from Sandoz US, a leading provider of generic pharmaceuticals and biosimilars.
